Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | GABRA1 | P14867 | 5/20 | 0.56 |
| ▸ | GABRA5 | P31644 | 5/20 | 0.56 |
| ▸ | GABRA3 | P34903 | 5/20 | 0.56 |
| ▸ | GABRA2 | P47869 | 5/20 | 0.56 |
| ▸ | GABRB2 | P47870 | 4/20 | 0.56 |
| ▸ | GABRG2 | P18507 | 3/20 | 0.56 |
| ▸ | GABRB3 | P28472 | 3/20 | 0.56 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.51 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.49 |
| ▸ | TUBB | P07437 | 1/20 | 0.49 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.49 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.49 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.49 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.49 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.49 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.49 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.49 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.49 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1365846 | 0.92 | GABRA1 (0.69) | KMT2AGABRA1GABRA5GABRA3GABRA2 | |
| SCHEMBL5490530 | 0.81 | TUBB4A (0.55) | KMT2AGABRA1GABRA5GABRA3GABRA2 | |
| SCHEMBL1421181 | 0.80 | KMT2A (0.82) | KMT2AGABRA1GABRA5GABRA3GABRA2 | |
| SCHEMBL5034663 | 0.76 | KMT2A (0.54) | KMT2AGABRA1GABRA5GABRA3GABRA2 | |
| SCHEMBL30094485 | 0.73 | SMN1; SMN2 (0.59) | KMT2AGABRA1GABRA5GABRA3GABRA2 | |
| SCHEMBL16239021 | 0.73 | SMN1; SMN2 (0.59) | KMT2AGABRA1GABRA5GABRA3GABRA2 | |
| Ro-052921 SCHEMBL29979594 | 0.72 | GABRA1 (1.00) | KMT2AGABRA1GABRA5GABRA3GABRA2 | |
| Ro-052921 SCHEMBL1365706 | 0.72 | GABRA1 (1.00) | KMT2AGABRA1GABRA5GABRA3GABRA2 | |
| SCHEMBL5042572 | 0.71 | TUBB4A (0.61) | KMT2AGABRA1GABRA5GABRA3GABRA2 | |
| SCHEMBL5349682 | 0.71 | TUBB4A (0.72) | KMT2AGABRA1GABRA5GABRA3GABRA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040152888-A1 | Cyclic nucleotide phosphodiesterase inhibitors, preparation and uses thereof | BAY CITY CAPITAL LLC | 2004-08-05 | — | — | US | claimed |
| US-7250410-B2 | Cyclic nucleotide phosphodiesterase inhibitors, preparation and uses thereof | VIA PHARMACEUTICALS, INC. (US) | 2007-07-31 | — | — | US | disclosed |
| US-20040152888-A1 | Cyclic nucleotide phosphodiesterase inhibitors, preparation and uses thereof | BAY CITY CAPITAL LLC | 2004-08-05 | — | — | US | disclosed |
| EP-1392663-A2 | CYCLIC NUCLEOTIDE PHOSPHODIESTERASE INHIBITORS, PREPARATION AND USES THEREOF | NEURO3D (FR) | 2004-03-03 | — | — | EP | disclosed |
| WO-2002098865-A2 | CYCLIC NUCLEOTIDE PHOSPHODIESTERASE INHIBITORS, PREPARATION AND USES THEREOF | NEURO3D (FR) | 2002-12-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040152888-A1 | Cyclic nucleotide phosphodiesterase inhibitors, preparation and uses thereof | PDE7A, PDE3B, PDE3A | KMT2A 3175/4885GABRA1 92/4885GABRA5 98/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.